Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 2
1995 1
1996 1
1999 1
2001 1
2003 4
2004 1
2005 1
2006 1
2009 2
2010 2
2013 1
2014 2
2020 1
2021 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Clinical and biochemical impact of vitamin B6 deficiency in primary sclerosing cholangitis before and after liver transplantation.
Braadland PR, Bergquist A, Kummen M, Bossen L, Engesæter LK, Reims HM, Björk I, Grzyb K, Abildgaard A, Småstuen MC, Folseraas T, Trøseid M, Ulvik A, Ueland PM, Melum E, Line PD, Høivik ML, Grønbæk H, Karlsen TH, Vesterhus M, Hov JR. Braadland PR, et al. J Hepatol. 2023 Oct;79(4):955-966. doi: 10.1016/j.jhep.2023.05.038. Epub 2023 Jun 14. J Hepatol. 2023. PMID: 37328069 Free article.
BACKGROUND AND AIMS: We previously demonstrated that people with primary sclerosing cholangitis (PSC) had reduced gut microbial capacity to produce active vitamin B6 (pyridoxal 5'-phosphate [PLP]), which corresponded to lower circulating PLP levels and poor o …
BACKGROUND AND AIMS: We previously demonstrated that people with primary sclerosing cholangitis (PSC) had reduced gut m …
Altered Gut Microbial Metabolism of Essential Nutrients in Primary Sclerosing Cholangitis.
Kummen M, Thingholm LB, Rühlemann MC, Holm K, Hansen SH, Moitinho-Silva L, Liwinski T, Zenouzi R, Storm-Larsen C, Midttun Ø, McCann A, Ueland PM, Høivik ML, Vesterhus M, Trøseid M, Laudes M, Lieb W, Karlsen TH, Bang C, Schramm C, Franke A, Hov JR. Kummen M, et al. Gastroenterology. 2021 Apr;160(5):1784-1798.e0. doi: 10.1053/j.gastro.2020.12.058. Epub 2020 Dec 31. Gastroenterology. 2021. PMID: 33387530 Free PMC article.
BACKGROUND & AIMS: To influence host and disease phenotype, compositional microbiome changes, which have been demonstrated in patients with primary sclerosing cholangitis (PSC), must be accompanied by functional changes. ...
BACKGROUND & AIMS: To influence host and disease phenotype, compositional microbiome changes, which have been demonstrated in patients w …
Chemoprevention of colorectal cancer in ulcerative colitis.
Croog VJ, Ullman TA, Itzkowitz SH. Croog VJ, et al. Int J Colorectal Dis. 2003 Sep;18(5):392-400. doi: 10.1007/s00384-002-0476-6. Epub 2003 Feb 6. Int J Colorectal Dis. 2003. PMID: 12904996 Review.
Both duration and extent of UC are important risk factors for CRC, as is the presence of primary sclerosing cholangitis, family history of CRC, and (in some studies) early age at diagnosis of UC. ...Ursodeoxycholic acid has been shown to reduce the risk of ne …
Both duration and extent of UC are important risk factors for CRC, as is the presence of primary sclerosing cholangitis …
Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis.
Pardi DS, Loftus EV Jr, Kremers WK, Keach J, Lindor KD. Pardi DS, et al. Gastroenterology. 2003 Apr;124(4):889-93. doi: 10.1053/gast.2003.50156. Gastroenterology. 2003. PMID: 12671884 Clinical Trial.
In addition, a recent report suggests that it also may decrease the risk for developing colorectal dysplasia in patients with ulcerative colitis (UC) and primary sclerosing cholangitis (PSC). We sought to evaluate the effect of UDCA on colorectal neoplasia in …
In addition, a recent report suggests that it also may decrease the risk for developing colorectal dysplasia in patients with ulcerative col …
[Hepatocellular carcinoma: occurrence, risk factors, biomarkers].
Fehér J, Lengyel G. Fehér J, et al. Orv Hetil. 2010 Jun 6;151(23):933-40. doi: 10.1556/OH.2010.28900. Orv Hetil. 2010. PMID: 20494888 Review. Hungarian.
Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related death worldwide. Primary hepatocellular carcinoma can be found most frequently (80-90 %) in patients with liver cirrhosis. ...Other predisposing causes can be: non-alcoholic steatohepatitis (NA …
Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related death worldwide. Primary hepatocellular carcinoma can …
[Ulcerative colitis. Cancer prevention].
Schmiegel W, Pox C, Kroesen A. Schmiegel W, et al. Z Gastroenterol. 2004 Sep;42(9):1014-8. doi: 10.1055/s-2004-813513. Z Gastroenterol. 2004. PMID: 15455276 German. No abstract available.
Prevalence of gastric parietal cell antibodies and intrinsic factor antibodies in primary biliary cirrhosis.
Liaskos C, Norman GL, Moulas A, Garagounis A, Goulis I, Rigopoulou EI, Dalekos GN. Liaskos C, et al. Clin Chim Acta. 2010 Mar;411(5-6):411-5. doi: 10.1016/j.cca.2009.12.012. Epub 2009 Dec 16. Clin Chim Acta. 2010. PMID: 20026019
METHODS: 157 PBC patients and 357 controls (73 with autoimmune hepatitis (AIH), 35 primary sclerosing cholangitis (PSC), 45 HBV, 37 HCV, 36 alcoholic liver disease (ALD), 35 non-alcoholic fatty liver disease (NAFLD) and 96 healthy) were investigated for IgG-i …
METHODS: 157 PBC patients and 357 controls (73 with autoimmune hepatitis (AIH), 35 primary sclerosing cholangitis (PSC) …
Basic research supported developments of chemotherapy in nonresectable isolated colorectal liver metastases to a protocol of hepatic artery infusion using mitoxantrone, 5-FU + folinic acid and mitomycin C.
Link KH, Kornmann M, Leder G, Pillasch AF, Sunelaitis E, Schatz M, Pressmar J, Beger HG. Link KH, et al. Gan To Kagaku Ryoho. 1999 Feb;26(3):269-81. Gan To Kagaku Ryoho. 1999. PMID: 10065089 Review.
The benefit of HAI with 5-FUDR, although recommended as treatment for CRLM, is severely compromised by the 5-FUDR induced hepatotoxicity, leading eventually to sclerosing cholangitis (SC)/liver scirrhosis. We have stepwise developed a protocol for HAI of CRLM, which …
The benefit of HAI with 5-FUDR, although recommended as treatment for CRLM, is severely compromised by the 5-FUDR induced hepatotoxicity, le …
[Radionuclide imaging in hepatobiliary disease].
Aburano T. Aburano T. Kaku Igaku. 1995 Jun;32(6):599-603. Kaku Igaku. 1995. PMID: 7674571 Review. Japanese.
In particular, the discrimination among the disease entities of chronic intermittent intrahepatic cholestasis including primary biliary cirrhosis, primary sclerosing cholangitis and juvenile intrahepatic bile duct hypoplasia can be made. ...
In particular, the discrimination among the disease entities of chronic intermittent intrahepatic cholestasis including primary bilia …
20 results